BridgeMD
Tests treatment safety and results for Myotonic Dystrophy
Official title A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1
ClinicalTrials.gov ID: NCT06844214
What this study is testing
What is SAR446268?
SAR446268 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for myotonic dystrophy.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a Phase 1/Phase 2 open-label single arm, multicenter, and multinational study with SAR446268 for treatment of male and female participants 10 to 55 years old with non-congenital myotonic dystrophy (DM) type 1 (DM1). The purpose of this study is to evaluate the safety and efficacy of SAR446268 in knocking down dystrophia myotonica protein kinase (DMPK) messenger ribonucleic acid (mRNA) levels and improving neuromuscular function in DM1 participants receiving a single intravenous (IV) administration of SAR446268.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 10 to 55
You may be able to join if
- Participants are eligible to be included in the study only if all of the following criteria apply:
- For Part A, participants must be 18 to 55 years of age inclusive, at the time of signing the informed consent.
- For Part B, participants must be as follows:
- 10 to 17 years of age inclusive, at the time of signing the informed consent or,
- 18 to 55 years of age inclusive, at the time of signing the informed consent.
You likely can't join if
- Participants are excluded from the study if any of the following criteria apply:
- Participants with neutralizing antibodies against the AAV.SAN011 capsid
- Participants with left ventricular ejection fraction \<50%
- Participants with liver or biliary disease defined as having at least one of the following:
- ALT \>3 x ULN and AST \>3 x ULN
- Alkaline phosphatase \>3 x ULN
See the full eligibility criteria
- Participants are eligible to be included in the study only if all of the following criteria apply:
- For Part A, participants must be 18 to 55 years of age inclusive, at the time of signing the informed consent.
- For Part B, participants must be as follows:
- 10 to 17 years of age inclusive, at the time of signing the informed consent or,
- 18 to 55 years of age inclusive, at the time of signing the informed consent.
- Participants with non-congenital onset DM1
- Participants presenting with signs of DM1 including myotonia and muscle weakness, as diagnosed previously by a clinician based on medical history.
- Participants with genetic diagnosis of DM1 [cytosine-thymine-guanine (CTG) repeat length ≥50 in one allele from medical history]
- Participants who can walk independently for at least 10 meters at screening (orthoses and ankle braces allowed).
- Participants are excluded from the study if any of the following criteria apply:
- Participants with neutralizing antibodies against the AAV.SAN011 capsid
- Participants with left ventricular ejection fraction \<50%
- Participants with liver or biliary disease defined as having at least one of the following:
- ALT \>3 x ULN and AST \>3 x ULN
- Alkaline phosphatase \>3 x ULN
- Total bilirubin \>1.5 x ULN (unless has a genetically confirmed diagnosis of Gilbert's syndrome)
- Direct bilirubin ≥1.5 x ULN
- Participants with International normalized ratio \>1.5
- Participants with renal disease defined as:
- Serum creatinine \>1.5 x ULN and/or estimated glomerular filtration rate \<60 mL/min/1.73 m2 as determined by Chronic Kidney Disease Epidemiology Collaboration (2021) for those age ≥18 years and Bedside Schwartz...
- Participants with chronic respiratory insufficiency and on long term/hull-time ventilatory assistance requiring at least 6 hours per day for at least 21 consecutive days.
- Participants with contraindication to corticosteroid or with conditions that could worsen in the presence of corticosteroids, as determined by the Investigator.
- Participants with active hepatitis B or C infection; HBsAg (+), or HCV RNA (+), or current antiviral therapy for either.
- Participants with HBcAb (+) who are not amenable for prophylactic anti-HBV therapy or pre-emptive therapy guided by serial HBV DNA monitoring during the corticosteroids therapy.
- Participants at high risk for tuberculosis reactivation during the corticosteroids therapy as determined by the Investigator.
- Participants with a known HIV infection
- Participants with serious intercurrent illness that, in the opinion of the Investigator, would preclude participation in the study or potentially decrease survival.
- Participants with recent history of or current drug or alcohol abuse in the past 12 months prior to screening.
- Participants with history of tibialis anterior biopsy within 12 weeks from Day 1 or planning to undergo tibialis anterior biopsies during the duration of this clinical trial.
- Participants with significant developmental delay, intellectual disability, or behavioral neuropsychiatric manifestations as determined by the Investigator.
- Participants with previous systemic corticosteroids treatment at doses of \>5 mg/day within 15 days of Day 1
- Participants with previous treatment with anti-myotonic medication within 15 days of Day 1
- Participants not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.
- Participants who have been classified as severe cardiac risk by the Investigator. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical...
The study team makes the final eligibility decision.
Where it's taking place
- Gainesville, Florida, United States
- Tampa, Florida, United States
- New York, New York, United States
- Richmond, Virginia, United States
- Buenos Aires, Argentina
- Brisbane, Queensland, Australia
- Montreal, Quebec, Canada
- Ramat Gan, Israel
- Newcastle upon Tyne, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 10 years to 55 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Gainesville, Florida, United States; Tampa, Florida, United States; New York, New York, United States; Richmond, Virginia, United States; Buenos Aires, Argentina; Brisbane, Queensland, Australia and 3 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.